New Treatment Triggers Self-Destruction of Pancreatic Cancer Cells

Written on |
Research conducted on human pancreatic tumours transplanted in mice reveals promising results, TAU researchers say Pancreatic cancer is resistant to all current treatments. Patients have extremely poor chances of surviving for five years after being diagnosed. A new Tel Aviv University study finds that a small molecule has the ability to induce the self-destruction of pancreatic cancer cells. The research was conducted with xenografts — transplantations of human pancreatic cancer into immunocompromised mice. The treatment reduced the number of cancer cells by 90% in the developed tumors a month after being administered. The research holds great potential for the development of a new effective therapy to treat this aggressive cancer in humans. The study was led by Prof. Malca Cohen-Armon and her team at TAU’s Sackler Faculty of Medicine, in collaboration with Dr. Talia Golan’s team at the Cancer Research Center at Sheba Medical Center. It was published in the journal Oncotarget on October 22. “In research published in 2017, we discovered a mechanism that causes the self-destruction of human cancer cells during their duplication (mitosis) without affecting normal cells,” explains Prof. Cohen-Armon. “We have now harnessed this information to efficiently eradicate human pancreatic cancer cells in xenografts. The current results were obtained using a small molecule that evokes this self-destruction mechanism in a variety of human cancer cells. “The mice were treated with a molecule called PJ34, which is permeable in the cell membrane but affects human cancer cells exclusively. This molecule causes an anomaly during the duplication of human cancer cells, provoking their rapid cell death. Thus, cell multiplication itself resulted in cell death in the treated cancer cells.” A month after being injected with PJ34 daily for 14 days, the pancreatic cancer cells in the tumors of the treated mice experienced a relative drop of 90%. In one mouse, the tumor completely disappeared. “It is important to note that no adverse effects were observed, and there were no changes in the weight gain of the mice, nor in their behavior,” says Prof. Cohen-Armon. This mechanism acts efficiently in other types of cancer resistant to current therapies. The molecule PJ34 is being tested in pre-clinical trials according to FDA regulations before clinical trials begin.  

Related posts

Medicinal Cannabis Oil Effective for Treating Autism

22 December 2021

TAU Students Racing Towards a Greener Campus

21 December 2021

Parent Smartphone Use Could Harm Child Development

20 December 2021

Breakthrough TAU Discovery Key to Reversing ALS

17 December 2021

Experimental Drug Displays Effectiveness in Treating Symptoms of Autism and Alzheimer’s Disease

16 December 2021

New Ethical Code for World Research of Ancient DNA

15 December 2021

Saving Lives with Artificial Intelligence

9 December 2021

TAU Experts on Omicron: “Don’t Panic”

7 December 2021

Britain and Israel Team Up on Challenge of Healthy Ageing

11 November 2021

TAU Researchers Identify COVID Proteins that Cause Strokes and Heart Attacks

8 November 2021

Help A Friend Out?

7 October 2021

Can’t Multitask Anymore?

6 October 2021

Why Do We Squabble Over The AC?

5 October 2021

The Immune System’s Double Agents

5 October 2021

Recruiting ‘Fighting Cells’ to Destroy Tumors

14 September 2021

TAU Team Reverses Early Signs of Alzheimer’s

10 September 2021

Victoria

Tok Corporate Centre, Level 1,
459 Toorak Road, Toorak VIC 3142
Phone: +61 3 9296 2065
Email: office@aftau.asn.au

New South Wales

P.O. Box 4044, Maroubra South,
NSW 2035
Phone: +61 418 465 556
Email: davidsolomon@aftau.org.au

Western Australia

P O Box 36, Claremont,
WA  6010
Phone: :+61 411 223 550
Email: clivedonner@thelinqgroup.com